SY-162(SY-162) - 药物靶点：PLG_专利_临床

概要

基本信息

药物类型

酶

别名

Recombinant staphylokinase variant

靶点

PLG

作用机制

PLG刺激剂(纤溶酶原刺激剂)

治疗领域

心血管疾病

在研适应症-

非在研适应症

外周动脉疾病外周动脉闭塞性疾病静脉血栓栓塞+ [1]

原研机构

Katholieke Universiteit Leuven

在研机构-

非在研机构

Thrombogenics, Inc.

Katholieke Universiteit Leuven

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 SY-162 相关的临床结果

登录后查看更多信息

100 项与 SY-162 相关的转化医学

登录后查看更多信息

100 项与 SY-162 相关的专利（医药）

登录后查看更多信息

1

项与 SY-162 相关的文献（医药）

2007-08-01·Journal of Thrombosis and Thrombolysis4区 · 医学

A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion

4区 · 医学

Article

作者: Marguerite Stas ; Godelieve Goossens ; Peter Verhamme ; Désiré Collen ; Geert Maleux

BACKGROUNDWe investigated the safety and efficacy of several dosing regimens of catheter-directed staphylokinase (SY162) bolus administration for the treatment of long-term venous access catheter occlusion.METHODSThis open-label, ascending dose study enrolled 24 subjects. Three doses of SY162 were evaluated in three cohorts (0.15 mg, 0.3 mg and 0.45 mg) with eight subjects each. Catheter function was evaluated 30 min after the first bolus administration. In case of incomplete catheter function restoration, a second bolus was administered with reassessment of catheter function 30 min thereafter. Cathetergram was repeated to assess thrombus resolution.RESULTSComplete restoration of catheter withdrawal function was observed in 2 (25%), 1 (13%) and 7 (88%) subjects after the first bolus in the first, second and third cohort respectively and in 4 (50%), 7 (88%) and 7 (88%) patients after the second administration of SY162. There were no bleeding complications nor other adverse events related to SY162.CONCLUSIONSThe doses tested in this trial were well tolerated and safe. A dose-response effect within the dose range tested was observed. A 2 ml bolus injection of 0.45 mg SY162 resulted in optimal efficacy after 30 min.

100 项与 SY-162 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
外周动脉疾病	临床2期	-	Thrombogenics, Inc.	-
外周动脉疾病	临床2期	-	Katholieke Universiteit Leuven	-
外周动脉闭塞性疾病	临床2期	比利时	Thrombogenics, Inc.	-
静脉血栓栓塞	临床2期	-	Thrombogenics, Inc.	-
静脉血栓栓塞	临床2期	-	Katholieke Universiteit Leuven	-
静脉血栓形成	临床2期	比利时	Thrombogenics, Inc.	-